Ultimately, this strategy can be applicable to other “undruggable” transcriptional factor targets presented on the surface of tumor cells in the form of peptide-loaded MHC class I/II complexes, including brachyury, a driver of EMT in TNBC demonstrating considerable promise as a clinical target of cancer vaccines [37-39]. The gene discussed is TBX1; the disease is cancer.